Skip to content
10-Q

Quarterly Report

NEUROCRINE BIOSCIENCES INC NBIX

0000914475-25-000100

← back to feed
Filed
May 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 98.97M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $522.9M
Current Liabilities Q1 2025 · Dec 31, 2024 $507.7M
Total Liabilities Q1 2025 · Mar 31, 2025 $1.15B
Total Liabilities Q1 2025 · Dec 31, 2024 $1.13B
Current Assets Q1 2025 · Mar 31, 2025 $1.64B
Current Assets Q1 2025 · Dec 31, 2024 $1.72B
Total Assets Q1 2025 · Mar 31, 2025 $3.69B
Total Assets Q1 2025 · Dec 31, 2024 $3.72B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $233M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $396.3M
Shares Diluted Q1 2025 · Mar 31, 2024 103.6M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $0
Capex Q1 2025 · Mar 31, 2024 $11.2M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $130.3M
Stockholders Equity Q1 2025 · Mar 31, 2024 $2.39B
Stockholders Equity Q1 2025 · Dec 31, 2023 $2.23B
Eps Diluted Q1 2025 · Mar 31, 2024 $0.42
Eps Basic Q1 2025 · Mar 31, 2024 $0.43
Sga Expense Q1 2025 · Mar 31, 2024 $243.1M
Net Income Q1 2025 · Mar 31, 2024 $43.4M
Operating Income Q1 2025 · Mar 31, 2024 $99.3M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $7.5M
Revenue Q1 2025 · Mar 31, 2024 $515.3M